Activation of nicotinamide N-methyltransferase gene promoter by hepatocyte nuclear factor-1β in human papillary thyroid cancer cells

Molecular Endocrinology

Volumn 19, Issue 2, 2005, Pages 527-539

  Xu, Jimin ^a   Capezzone, Marco ^a   Xu, Xiao ^a   Hershman, Jerome M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Vet Aff Gtr Los Angeles H   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 1BETA; LUCIFERASE; NICOTINAMIDE METHYLTRANSFERASE; NUCLEAR FACTOR I; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL SPECIFICITY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; GEL BLOT ANALYSIS; GENE; GENE ACTIVATION; GENE CONSTRUCT; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; NICOTINAMIDE N METHYLTRANSFERASE GENE; ONCOCYTOMA; OVARY FOLLICLE CELL; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CANCER; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

ADENOCARCINOMA, PAPILLARY; BASE SEQUENCE; BINDING SITES; BLOTTING, WESTERN; CATALYSIS; CELL LINE; CELL LINE, TUMOR; CELL NUCLEUS; CLONING, MOLECULAR; DNA-BINDING PROTEINS; ENZYME ACTIVATION; GENE DELETION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; LUCIFERASES; METHYLTRANSFERASES; MOLECULAR SEQUENCE DATA; MUTATION; NICOTINAMIDE N-METHYLTRANSFERASE; PLASMIDS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID GLAND; THYROID NEOPLASMS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 13544252543     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2004-0215     Document Type: Article

References (47)

1. Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK, Holzer S 2000 Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. Cancer 89:202-217
2. Xu J, Moatamed F, Caldwell JS, Walker JR, Kraiem Z, Taki K, Brent GA, Hershman JM 2003 Enhanced expression of nicotinamide N-methyltransferase in human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 88:4990-4996
3. Aksoy S, Szumlanski CL, Weinshilboum RM 1994 Human liver nicotinamide N-methyltransferase. cDNA cloning, expression, and biochemical characterization. J Biol Chem 269:14835-14840
4. Alston TA, Abeles RH 1988 Substrate specificity of nicotinamide methyltransferase isolated from porcine liver. Arch Biochem Biophys 260:601-608
5. Clark JB, Ferris GM, Pinder S 1971 Inhibition of nuclear NAD nucleosidase and poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5′-methyl nicotinamide. Biochim Biophys Acta 238:82-85
6. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA 2002 Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 277:45099-45107
7. Jackson MD, Schmidt MT, Oppenheimer NJ, Denu JM 2003 Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases. J Biol Chem 278:50985-50998
8. Landry J, Slama JT, Sternglanz R 2000 Role of NAD(+) in the deacetylase activity of the SIR2-like proteins. Biochem Biophys Res Commun 278:685-690
9. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W 2001 Negative control of p53 by Sir2α promotes cell survival under stress. Cell 107:137-148
10. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA 2001 hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107:149-159
11. Sandmeier JJ, Celic I, Boeke JD, Smith JS 2002 Telomeric and rDNA silencing in Saccharomyces cerevisiae are dependent on a nuclear NAD(+) salvage pathway. Genetics 160:877-889
12. Anderson RM, Bitterman KJ, Wood JG, Medvedik O, Cohen H, Lin SS, Manchester JK, Gordon JI, Sinclair DA 2002 Manipulation of a nuclear NAD+ salvage pathway delays aging without altering steady-state NAD+ levels. J Biol Chem 277:18881-18890
13. Gallo CM, Smith Jr DL, Smith JS 2004 Nicotinamide clearance by Pnc1 directly regulates Sir2-mediated silencing and longevity. Mol Cell Biol 24:1301-1312
14. Anderson RM, Bitterman KJ, Wood JG, Medvedik O, Sinclair DA 2003 Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature 423:181-185
15. Aoyama K, Matsubara K, Kondo M, Murakawa Y, Suno M, Yamashita K, Yamaguchi S, Kobayashi S 2001 Nicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurosci Lett 298:78-80
16. Fukushima , Kaetsu A, Lim H, Moriyama M 2002 Possible role of 1-methylnicotinamide in the pathogenesis of Parkinson's disease. Exp Toxicol Pathol 53:469-473
17. Parsons RB, Smith SW, Waring RH, Williams AC, Ramsden DB 2003 High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson's disease. Neurosci Lett 342:13-16
18. Li K, Prow T, Lemon SM, Beard MR 2002 Cellular response to conditional expression of hepatitis C virus core protein in Huh7 cultured human hepatoma cells. Hepatology 35:1237-1246
19. Hanazawa Y, Sato K, Kuroiwa N, Ogawa M, Kuriyama A, Asanagi M, Kato N, Moriyama Y, Horitsu K, Fujimura S 1994 Characterization of nicotinamide methyltransferase in livers of mice bearing Ehrlich ascites tumors: preferential increase of activity. Tumour Biol 15:7-16
20. Nakagawa K, Miyazaki M, Okui K, Kato N, Moriyama Y, Fujimura S 1991 N1-methylnicotinamide level in the blood after nicotinamide loading as further evidence for malignant tumor burden. Jpn J Cancer Res 82:1277-1283
21. Okamura A, Ohmura Y, Islam MM, Tagawa M, Horitsu K, Moriyama Y, Fujimura S 1998 Increased hepatic nicotinamide N-methyltransferase activity as a marker of cancer cachexia in mice bearing colon 26 adenocarcinoma. Jpn J Cancer Res 89:649-656
22. Ohkubo M, Sakiyama S, Fujimura S 1983 Increase of nicotinamide methyltransferase and N1-methyl-nicotinamide oxidase activities in the livers of the rats administered alkylating agents. Cancer Lett 21:175-181
23. Hoshino J, Kuhne U, Kroger H 1982 Methylation of nicotinamide in rat liver cytosol and its correlation with hepatocellular proliferation. Biochim Biophys Acta 719:518-526
24. Kassem HSh, Sangar V, Cowan R, Clarke N, Margison GP 2002 A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder cancer. Int J Cancer 101:454-460
25. Tsuchiya A, Sakamoto M, Yasuda J, Chums M, Ohta T, Ohki M, Yasugi T, Taketani Y, Hirohashi S 2003 Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1β as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 163:2503-2512
26. Rey-Campos J, Chouard T, Yaniv M, Cereghini S 1991 vHNF1 is a horneoprotein that activates transcription and forms heterodimers with HNF1. EMBO J 10:1445-1457
27. Bach I, Mattei MG, Cereghini S, Yaniv M 1991 Two members of an HNF1 horneoprotein family are expressed in human liver. Nucleic Acids Res 19:3553-3559
28. Mendel DB, Hansen LP, Graves MK, Conley PB, Crabtree R 1991 HNF-1 α and HNF-1 β (vHNF-1) share dimerization and homeo domains, but not activation domains, and form heterodimers in vitro. Genes Dev 5:1042-1056
29. Bai Y, Pontoglio M, Hiesberger T, Sinclair AM, Igarashi P 2002 Regulation of kidney-specific Ksp-cadherin gene promoter by hepatocyte nuclear factor-1β. Am J Physiol Renal Physiol 283:F839-F851
30. Boudreau F, Zhu Y, Traber PG 2001 Sucrase-isomaltase gene transcription requires the hepstocyte nuclear factor-1 (HNF-1) regulatory element and is regulated by the ratio of HNF-1 α to HNF-1 β. J Biol Chem 276:32122-32128
31. Hu C, Perlmutter DH 2002 Cell-specific involvement of HNF-1 β in α(1)-antitrypsin gene expression in human respiratory epithelial cells. Am J Physiol Lung Cell Mol Physiol 282:L757-L765
32. Menoud PA, Matthies R, Hofsteenge J, Nagamine Y 1993 Purification and cDNA cloning of a transcription factor which functionally cooperates within a cAMP regulatory unit in the porcine uPA gene. Nucleic Acids Res 21:1845-1852
33. Song YH, Ray K, Liebhaber SA, Cooke NE 1998 Vitamin D-binding protein gene transcription is regulated by the relative abundance of hepatocyte nuclear factors 1 α and 1β. J Biol Chem 273:28408-28418
34. Soubt MK, Marksitzer R, Menoud PA, Nagamine Y 1998 Role of tissue-specific transcription factor LFB3 in a cyclic AMP-responsive enhancer of the urokinase-type plasminogen activator gene in LLC-PK1 cells. Mol Cell Biol 18:4698-4706
35. Bach I, Yaniv M 1993 More potent transcriptional activators or a transdominant inhibitor of the HNF1 homeo-protein family are generated by alternative RNA processing. EMBO J 12:4229-4242
36. Coffinier C, Barra J, Babinet C, Yaniv M 1999 Expression of the vHNF1/HNF1β homeoprotein gene during mouse organogenesis. Mech Dev 89:211-213
37. Serfas MS, Tyner AL 1993 HNF-1 α and HNF-1 β expression in mouse intestinal crypts. Am J Physiol 265:G506-G513
38. Horikawa Y, Iwasaki N, Hara M, Furuta H, Hinokio Y, Cockburn BN, Lindner T, Yamagata K, Ogata M, Tomonaga O, Kuroki H, Kasahara T, Iwamoto Y, Bell GI 1997 Mutation in hepatocyte nuclear factor-1 β gene (TCF2) associated with MODY. Nat Genet 17:384-385
39. Lindner TH, Njolstad PR, Horikawa Y, Bostad L, Bell GI, Sovik O 1999 A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1 β. Hum Mol Genet 8:2001-2008
40. Locker J, Ghosh D, Luc PV, Zheng J 2002 Definition and prediction of the full range of transcription factor binding sites - the hepatocyte nuclear factor 1 dimeric site. Nucleic Acids Res 30:3809-3817
41. Soutoglou E, Papafotiou G, Katrakili N, Talianidis I 2000 Transcriptional activation by hepatocyte nuclear factor-1 requires synergism between multiple coactivator proteins. J Biol Chem 275:12515-12520
42. Smith SB, Gasa R, Watada H, Wang J, Griffen SC, German MS 2003 Neurogenin3 and hepatic nuclear factor 1 cooperate in activating pancreatic expression of Pax4. J Biol Chem 278:38254-38259
43. van Wering HM, Huibregtse IL, van der Zwan SM, de Bie MS, Dowling LN, Boudreau F, Rings EH, Grand RJ, Krasinski SD 2002 Physical interaction between GATA-5 and hepatocyte nuclear factor-1 α results in synergistic activation of the human lactase-phlorizin hydrolase promoter. J Biol Chem 277:27659-27667
44. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A 2004 Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23:7436-7440
45. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457
46. Ohta K, Pang XP, Berg L, Hershman JM 1997 Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the β-adrenergic receptor. J Clin Endocrinol Metab 82:2633-2638
47. Taki K, Kogai T, Kanamoto Y, Hershman JM, Brent GA 2002 A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3′,5′-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. Mol Endocrinol 16:2266-2282